GlassScriptPhysician profile
Nimisha Trivedi
NPI 1629074299
$10,688.43
in general payments reported to CMS, 2019-2025
37 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $892 · 2021: $2,278 · 2022: $1,951 · 2023: $1,186 · 2024: $1,831 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,633 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,632.93 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,850.81 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,317.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $978.02 | 2020-2025 | Vraylar, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $931.15 | 2021-2025 | |
| Glaxosmithkline, LLC. | $806.59 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $766.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $617.22 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $328.26 | 2019-2025 | |
| Shield Therapeutics INC | $299.02 | 2023-2025 | Accrufer |
| Allergan, INC. | $272.47 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.40 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $200.98 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $197.23 | 2022 | |
| Phathom Pharmaceuticals, INC. | $191.91 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.02 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $162.13 | 2019-2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $156.71 | 2019-2025 | Zoryve |
| Amarin Pharma, INC. | $153.90 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $126.27 | 2021 | |
| Exact Sciences Corporation | $109.93 | 2023-2024 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $103.04 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.08 | 2024-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $92.08 | 2020-2022 | |
| Medtronic, INC. | $89.33 | 2022-2024 | Venaseal |
| Corcept Therapeutics | $85.60 | 2024-2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $51.25 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $49.08 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Otsuka America Pharmaceutical, INC. | $45.85 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $36.19 | 2024 | Quviviq |
| Mylan Specialty L.P. | $34.93 | 2022-2023 | Yupelri |
| Verona Pharma, INC. | $29.46 | 2025 | Ohtuvayre |
| Radius Health, INC. | $21.01 | 2024 | Tymlos |
| Dexcom, INC. | $17.08 | 2024 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $15.78 | 2025 | Zenpep |
| Linus Health, INC. | $14.06 | 2023 | |
| Optos, INC. | $13.42 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimisha Trivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.